bevacizumab,panitumumab
roche,amgen,takeda
['rectal', 'colorectal', 'bevacizumab', 'paradigm']
editorial: the paradigm trial offers prospective evidence to support the use of anti-egfr therapy over bevacizumab in combination with chemotherapy in the frontline treatment of ras wild-type (wt), left-sided metastatic colorectal cancer. #aacr23 
JAMA #Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology.